David Melamed, PhD,  —

The first patient has been dosed in Stoke Therapeutics‘ Phase 1/2a MONARCH trial, which is investigating the safety, tolerability, and efficacy of STK-001 as a treatment for children and adolescents with Dravet syndrome. Enrollment in the trial is ongoing. People with Dravet, a severe type of epilepsy,…

Stoke Therapeutics has begun enrollment for its Phase 1/2a MONARCH study, investigating the safety, tolerability, and effectiveness of STK-001 in children and adolescents with Dravet syndrome. The MONARCH trial (NCT04442295) will recruit up to 48 patients with Dravet, from ages 2–18, at multiple centers…

Note: This story was updated June 15, 2020, to note that Ashish Sagrolikar is Zogenix’s chief commercial officer, not its CEO.  Pharmaceutical company Zogenix has launched “Shine Forward with Dravet,” an online resource to support the parents and siblings of children with Dravet syndrome. The new resource,…